Precision Optics Corporation Regains Compliance With Nasdaq Minimum Bid Price Requirement

Dec 22, 2004, 00:00 ET from Precision Optics Corporation, Inc.

    GARDNER, Mass., Dec. 22 /PRNewswire-FirstCall/ -- Precision Optics
 Corporation, Inc. (Nasdaq:   POCI) announced today that it received a letter
 from the Nasdaq Stock Market notifying the Company that the closing bid price
 of the Company's common stock has closed at $1.00 per share or greater for at
 least 10 consecutive business days, and that the Company has regained
 compliance with the minimum bid price requirement for continued listing on the
 Nasdaq SmallCap Market.
     About Precision Optics
     Precision Optics Corporation, a leading developer and manufacturer of
 advanced optical instruments since 1982, designs and produces high-quality
 optical thin film coatings, medical instruments, and other advanced optical
 systems.  The Company's medical instrumentation line includes laparoscopes,
 arthroscopes and endocouplers and a world-class product line of 3-D endoscopes
 for use in minimally invasive surgical procedures.
     The Company is currently developing specialty instruments incorporating
 its patent-pending LENSLOCK(TM) technology which ensures lower cost, easier
 repairability and enhanced durability as well as ultra-small instruments (some
 with lenses less than one millimeter in diameter) utilizing patent-pending
 micro-precision(TM) lens technology. The Company is also exploring new
 initiatives in single-molecule technology and nanotechnology for biomedical
 and other applications.
     Precision Optics Corporation is certified to the ISO 9001 Quality
 Standard, and complies with the FDA Good Manufacturing Practices and the
 European Union Medical Device Directive for CE Marking of its medical
 products.  The Company's Internet Website is .
     Forward-Looking Statements
     Forward-looking statements contained in this news release, including those
 related to the Company's products under development, are made under "safe
 harbor" provisions of the Private Securities Litigation Reform Act of 1995 and
 involve a number of risks and uncertainties that could materially affect
 future results. These risks and uncertainties, many of which are not within
 the Company's control, include, but are not limited to, the uncertainty and
 timing of the successful development of the Company's new products; the risks
 associated with reliance on a few key customers; the Company's ability to
 maintain compliance with requirements for continued listing on the NASDAQ
 SmallCap Market; the Company's ability to attract and retain personnel with
 the necessary scientific and technical skills, the timing and completion of
 significant orders; the timing and amount of the Company's research and
 development expenditures; the timing and level of market acceptance of
 customers' products for which the Company supplies components; performance of
 the Company's vendors; the ability of the Company to control costs associated
 with performance under fixed price contracts; and the continued availability
 to the Company of essential supplies, materials and services; and the other
 risk factors and cautionary statements listed from time to time in the
 Company's periodic reports filed with the Securities and Exchange Commission,
 including but not limited to, the Company's Annual Report on Form 10-KSB for
 the year ended June 30, 2004.

SOURCE Precision Optics Corporation, Inc.